Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial In Neuroblastoma Patients

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that it has initiated a Phase 2a clinical trial of Azedra (Ultratrace? iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma, a neuroendocrine cancer that primarily affects children. Azedra is already being evaluated in an ongoing dose-ranging clinical trial for pheochromocytoma in adults.

More: continued here

Filed under: Endocrinology on May 15th, 2008